Synthaverse S.A.

SVE

PLBMDLB00018

Pharmaceuticals

Market Closed - Warsaw S.E. Other stock markets 11:55:55 2024-04-26 am EDT			5-day change	1st Jan Change
4.9 ^PLN	+1.55%		-3.35%	+14.75%

Apr. 10	Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Ticker to SVE from BML

July 18, 2023 at 12:00 am EDT

Effective July 18, 2023, BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will change its Warsaw Stock Exchange stock ticker symbol to SVE from BML.

Latest news about Synthaverse S.A.

Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Synthaverse S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Ticker to SVE from BML	23-07-18	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Name to SYNTHAVERSE S.A	23-07-18	CI
BIOMED-LUBLIN WytwÃ³rnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-26	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) dropped from S&P Global BMI Index	22-09-19	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-07	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-26	CI
BIOMED-LUBLIN Wytw?rnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 13.398489 million in funding	21-09-26	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-31	CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Announces Earnings Results for the First Quarter of 2021	21-05-28	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm	21-05-03	CI
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-02	CI
Biomed-Lublin Secures PLN 29.2 Million in EU Financing for Construction of an R&D Center	20-10-01	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) added to S&P Global BMI Index	20-09-21	CI
BIOMED LUBLIN Announces Earnings Results for the First Half Year 2020	20-09-15	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 6.826041 million in funding	20-07-06	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transaction	19-06-27	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it has received PLN 4.8 million in funding	18-07-22	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 4.8 million in funding	17-11-30	CI
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna announced that it expects to receive PLN 4.01 million in funding	17-11-13	CI

Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SYNTHAVERSE S.A.	+14.75%	85.36M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B